Company: CSTL
Filing Date: 2025-04-09
Form Type: DEF 14A
Source: 0001447362-25-000054
Chunk: 0

Company: CASTLE BIOSCIENCES INC
Filing Date: 2025-04-09
Form: DEF 14A
Chunk 0
---
### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

#### SCHEDULE 14A INFORMATION

#### Proxy Statement Pursuant to Section 14(a) of the

#### Securities Exchange Act of 1934
<div align='center'>(Amendment No.___)</div>

Filed by the Registrant ☒

Filed by a party other than the Registrant ☐

Check the appropriate box:

| ☐ |     | Preliminary Proxy Statement                                                     |
| ☐ |     | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| ☒ |     | Definitive Proxy Statement                                                      |
| ☐ |     | Definitive Additional Materials                                                 |
| ☐ |     | Soliciting Material under § 240.14a-12                                          |

#### CASTLE BIOSCIENCES, INC.
<div align='center'>(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)</div>

Payment of Filing Fee (Check all boxes that apply):

| ☒ |     | No fee required                                                                                     |
| ☐ |     | Fee paid previously with preliminary materials                                                      |
| ☐ |     | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |

#### DEAR FELLOW STOCKHOLDERS,
I am pleased to invite you to Castle Biosciences’ 2025 Annual Meeting of Stockholders, being held Thursday, May 22, 2025, at 10 a.m. Central time. Our Annual Meeting offers a valuable opportunity to engage with you and seek your perspectives on matters important to Castle. The following Notice of Annual Meeting and accompanying Proxy Statement provide important details regarding the meeting.

Our efforts over the past year have positively impacted the care of thousands of patients, a success made possible through the dedication and passion of our incredible Castle team. Their unwavering commitment to our mission to improve health through our innovative tests that guide patient care was a key component driving our exceptional performance in 2024. We delivered full-year revenue of $332 million, representing growth of 51% over 2023, and saw 36% growth in our year-over-year total test report volume.

We are confident in our ability to sustain our strong momentum that is shaping the future of patient care and